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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on ‘cranberry extract powder’ as a novel food (NF)
submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council. The
NF contains about 55–60% proanthocyanidins (PACs). The Panel considers that the information
provided on the composition, the specifications, batch-to-batch variability and stability of the NF is
sufficient and does not raise safety concerns. Cranberry extract powder is produced from cranberry
juice concentrate through an ethanolic extraction using an adsorptive resin column to retain the
phenolic components. The Panel considers that the production process is sufficiently described and
does not raise concerns about the safety of the novel food. The NF is intended to be added to
beverages and yogurts to provide 80 mg PACs per serving. The target population is the adult general
population. The mean and 95th percentile estimates for the all-user intakes from all proposed food-
uses are 68 and 192 mg/day, respectively, for female adults, and 74 mg/day and 219 mg/day,
respectively, for male adults. Taking into account the composition of the novel food and the intended
use levels, the Panel considers that the consumption of the NF is not nutritionally disadvantageous.
While no animal toxicological studies have been conducted on the NF, a number of human clinical
studies have been conducted with cranberry products. Considering the composition, manufacturing
process, intake, history of consumption of the source and human data, the Panel considers that the
data provided do not give reasons for safety concerns. The Panel concludes that the cranberry extract
powder is safe as a food ingredient at the proposed uses and use levels.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on ‘cranberry extract powder’ as a novel food (NF)
ingredient submitted pursuant to Regulation (EC) No 258/971 of the European Parliament and of the
Council, taking into account the comments and objections of a scientific nature raised by Member
States. The assessment, which follows the methodology set in Commission Recommendation 97/618/
EC is based on the data supplied in the original application, the initial assessment by the competent
authority of France, the concerns and objections of the other Member States and the responses of the
applicant.
The NF is prepared from the juice concentrate of sound, mature berries of the cranberry cultivar
(Vaccinium macrocarpon). According to the specification, the NF contains 55–60% proanthocyanidins
(PACs) as measured by OSC-DMAC (colorimetric analysis using dimethylaminocinnamaldehyde (DMAC)
with isolated cranberry PACs as a standard compound). Other main constituents of the NF are
anthocyanins, other phenolic compounds such as flavonols, sugars and organic acids. The
Panel considers that the information provided on the composition, the specifications, batch-to-batch
variability and stability of the NF is sufficient and does not raise safety concerns.
Cranberry extract powder is produced from cranberry juice concentrate through an ethanolic
extraction using an adsorptive resin column to remove sugars and organic acids and to retain the
phenolic components which are eluted, concentrated and spray-dried to yield the powder. Silicon
dioxide is added as a flow agent and maltodextrin as a carrier. The manufacturing process is
performed according to good manufacturing practice (GMP). About 66 mL of pure (7.5 Brix) cranberry
juice is needed to produce 145 mg of cranberry extract containing 33–36 mg PACs (about 80 mg
measured by OSC-DMAC) and this amount approximately corresponds to a 240 mL serving of Ocean
Spray’s 27% ‘cranberry juice classic’ currently on the market. The Panel considers that the production
process is sufficiently described and does not raise concerns about the safety of the novel food.
The NF is intended to be added to fruit-flavoured drinks (regular and low calorie), isotonic drinks
(including electrolyte types), tea drinks (ready-to-drink, iced), vitamin enhanced waters, yogurts and
yogurt drinks with the intention to provide 80 mg PACs per serving (based on OSC-DMAC method).
According to the applicant, the target population is the adult general population and the NF is not
intended to be marketed to children.
When assuming that 240 mL of 27% cranberry juice contains on the average 156 mg PACs, the
mean and 95th percentile of an adult female consumer is about 200 and 1,200 mL, respectively,
cranberry juice per day. The corresponding mean and 95th percentile intakes of PACs from cranberry
juice would be about 130 and 780 mg PACs per day for adult females, and 108 and 246 mg for adult
males. For female adults, the mean and 95th percentile estimates for the all-user intakes of PACs from
all proposed food-uses of the NF were 68 mg/day and 192 mg/day, respectively. The mean and 95th
percentile estimates for the all-user intakes for male adults of PACs from all proposed food-uses also
were 74 and 219 mg/day, respectively.
Taking into account the composition of the novel food and the intended use levels, the
Panel considers that the consumption of the NF is not nutritionally disadvantageous.
While no animal toxicological studies have been conducted on the NF, a number of human clinical
studies have been conducted with cranberry products other than the NF. None of these studies have
indicated adverse effects caused by cranberry consumption. In addition, three clinical studies have
been conducted with the NF. The Panel notes that the PACs dose of these clinical studies is high as
compared to the conditions of use of the NF. The Panel considers these studies do not raise safety
concerns of the NF.
Based on the data provided, and considering the composition, manufacturing process, anticipated
intake, history of consumption of the source and human studies, the Panel considers that the
consumption of the cranberry extract powder under the proposed conditions of use does not raise
safety concerns.
The Panel concludes that the cranberry extract powder is safe as a food ingredient at the proposed
uses and use levels.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel
food ingredients (OJ L 43, 14.2.1997, p. 1). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1997R0258:
20090120:EN:PDF
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 20 September 2011, the company Ocean Spray Cranberries Inc. submitted a request in
accordance with Article 4 of the Novel Food Regulation (EC) No 258/97 to place on the market
cranberry extract powder as a novel food (NF) ingredient.
On 11 December 2014, the competent authority of France forwarded to the Commission its initial
assessment report, which came to the conclusion that cranberry extract powder meets the criteria for
acceptance of a NF defined in Article (3) 1 of Regulation (EC) No 258/97.
On 16 January 2015, the Commission forwarded the initial assessment report to the other Member
States. Several Member States submitted comments or raised objections.
The concerns of a scientific nature raised by the Member States can be summarised as follows:
• The specification of the product is incomplete. In particular, the application and the documents
submitted subsequently contain discrepancies in the information on the concentration of
proanthocyanidins (PACs) and intake amounts.
• There are no studies in children on the safety and tolerance of PACs intake at the 95th
percentile of the anticipated intake.
• The cumulative intake of polyphenols from the NF for children between 1 and 3 years of age
together with other sources of polyphenols in a child’s diet would bring total exposure to
polyphenols to a level 2–7 times higher than that of adults. Given that there are known
adverse effects related to the overconsumption of polyphenols, reassurance is required that
daily levels of total polyphenols exposure inclusive of the intakes from the NF would be safe
for children.
• Possible side effects can be observed from long-term elevated polyphenol intake, for example
inhibition of iron and folic acid absorption, interaction with other food components in the
stomach, such as inhibiting triglyceride absorption by restricting pancreatic lipase (Sugiyama
et al., 2007), interaction with carrier proteins (Faria et al., 2006), potential interaction with
warfarin (Pham and Pham, 2007).
• Information on the protein content is needed to confirm that an allergy risk is unlikely.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission
asks the European Food Safety Authority (EFSA) to provide a scientific opinion by carrying out the
additional assessment for cranberry extract powder as a novel food ingredient in the context of
Regulation (EC) No 258/97.
2. Data and methodologies
2.1. Data
The assessment of the safety of this novel food ingredient (NFI) is based on data supplied in the
original application, the initial assessment by the competent authority of France, the concerns and
objections of the other Member States and the responses of the applicant. The data are required to
comply with the information required for novel foods of Subclass 2.1: ‘the source of the novel food has
a history of food use in the Community’, i.e. structured schemes I, II, III, IX, X, XI, XII and XIII of
Commission Recommendation 97/618/EC. In the current opinion, these structured schemes are listed
in Sections 3.1–3.9. The intention of the applicant is to add ‘cranberry extract powder’ to beverages,
milk and other dairy products. The target population is the general population. This assessment
concerns only risk that might be associated with consumption under the proposed conditions of use,
and is not an assessment of the efficacy of the NF with regard to any claimed benefit.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29
July 1997 concerning the scientific aspects and the presentation of information necessary to support
applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
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3. Assessment
3.1. Specification of the Novel Food (NF)
The NF is prepared from the juice concentrate of sound, mature berries of the cranberry cultivar
(Vaccinium macrocarpon). The NF is a fine, free-flowing deep red powder obtained from spray drying
of chromatographically isolated Cranberry Extract Liquid – Type R, standardised to the PACs content
with maltodextrin as a carrier and silicon dioxide as a flow agent (Table 1).
Regarding heavy metals, the applicant provided information on the testing of three batches which
gave the following ranges: arsenic 71.9–95 ppb, cadmium < 10 ppb, mercury < 10 ppb and lead
42.3–110 ppb.
The applicant notes that the NF must comply with regulatory limits for pesticides, herbicides, heavy
metals, growth regulators and mycotoxins. In this regard, the applicant points out that the berry juice
concentrate used for the manufacture of the product in question complies with the maximum levels of
contaminants laid down in Regulation (EC) No 1881/2006. Tests were carried out on at least three
different production batches for PACs and the total phenolic content as well as for the content of
residual heavy metals (including As, Cd, Hg and Pb) and ethanol, and the content of the flow agent SiO2.
Table 1: Specifications proposed by the applicant
Parameters Range Method of Measurement
Moisture (% w/w) ≤ 4 Gravimetric, loss of drying (CEM microwave oven
or equivalent)
PACs (% DWB)
OSC-DMAC method(a),(c)
BL-DMAC method(b),(c)
55.0–60.0
15.0–18.0
OSC-DMAC (25 EtOH wash) using cranberry
extract response factor. BL-DMAC using
procyanidin A2 standard
Total phenolics
(GAE, % DWB)(c)
> 46.2 Folin–Ciocalteau using gallic acid standard
Solubility 100%, with no visible insoluble
particles
Powder should dissolve completely in 2 min with
agitation
Ethanol content (mg/kg) ≤ 100 AOCS Official method Ca 3b-87, hexane residues
in fats and oils, or equivalent
Screen analysis 100% through 30-mesh screen Rotap with hammer, 5 min
Appearance & aroma;
as powder
Free-flowing, deep red colour.
Earthy aroma with no burnt
character
Sensory
Heavy metals
Arsenic (ppm) < 3 EPA 200.8
Lead (ppm) < 2 EPA 200.8
Cadmium (ppm) < 10 EPA 200.8
Mercury (ppm) < 1 EPA 200.8
Microbiology
Yeast < 100 cfu/g Microbiological methods as described by AOAC(d),
APHA(e) or BAM(f) (FDA)Mould < 100 cfu/g
Aerobic plate count < 1,000 cfu/g
Coliforms < 3 mpn/g or < 10 cfu/g
Escherichia coli < 3 mpn/g or < 10 cfu/g
Salmonella Absent in 375 g composite
sample
PAC: proanthocyanidin; DWB: dry weight basis; GAE: gallic acid equivalent; cfu: colony forming unit; mpn: most probably
number.
(a): OSC-DMAC method (J. Agric. Food Chem. 1998).
(b): BL-DMAC method (J. Agric. Food Chem. 2010).
(c): The different values for these three parameters are due to the different methods used.
(d): AOAC (Association of Official Analytical Chemists or Association of Analytical Communities).
(e): APHA American Public Health Association).
(f): BAM (Bacteriological Analytical Manual, FDA).
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According to the specification, the NF contains 55–60% PACs as measured by OSC-DMAC
(colorimetric analysis using dimethylaminocinnamaldehyde (DMAC) with isolated cranberry PACs as a
standard compound). The PACs content was also analysed using the BL-DMAC method (colorimetric
analysis using DMAC with the procyanidin dimer A2 as a standard compound) with a content of
15–18%. Analytical data on the distribution of the PACs monomers, dimers, trimers and larger
polymers in the NF was provided.
Additional information provided by the applicant indicates that the NF also contains 3.2%
anthocyanins, 4.8% sugars and 6.0% organic acids. The residual protein content of the NF is 1.16%
as measured by the Dumas method with a limit of quantitation of 1 g/kg.
The Panel considers that the information provided on the composition, the specifications and the
batch-to-batch variability of the NF is sufficient and does not raise safety concerns.
3.1.1. Stability of the NF
Based on the analysis of the PAC content, of anthocyanins and total phenolics, the results of
stability tests demonstrate that the cranberry extract powder is stable for 30 months when stored in
dry conditions at 25°C. The applicant also provided results (PACs and total phenolic analyses)
indicating that cranberry extract powder is stable as incorporated at a level of 45 mg PAC per portion
(240 mL) into diet- or water-type beverages for up to 22 weeks at room temperature. Additional
stability testing of water-type beverages containing 70 mg PACs (measured by OSC-DMAC) per portion
(240 mL) stored at 32°C showed no appreciable change in PACs content during a 12-week period.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF.
3.2. Effect of the production process applied to the NF
Typically, cranberry juice contains sugars, organic acids and phenolic compounds (including
flavonols, flavan-3-ols, anthocyanins and PACs). Of the solid material in cranberry juice, 90% are
organic acids and sugars (Ocean Spray Cranberries internal compositional cranberry juice database).
These phenolic compounds are selectively isolated from the other components of cranberry juice to
yield cranberry extract.
The applicant provided a detailed description of the production process including a flowchart.
Cranberry extract powder is produced from cranberry juice concentrate through an ethanolic extraction
using an adsorptive resin column to remove sugars and organic acids, and to retain the phenolic
components which are eluted, concentrated and spray-dried to yield the powder. Silicon dioxide is
added as a flow agent and maltodextrin as a carrier. The material is packaged in two polyethylene
bags, each with a twist tie, and placed in a standard fibre drum. The outer bag contains one desiccant
sachet. A second desiccant sachet is placed at the top of the drum, outside the outer bag. Each drum
contains about 22.7 kg powder net.
The manufacturing process is performed according to good manufacturing practice (GMP). The
material shall be processed under sanitary conditions in accordance with GMP regulations FDA 21 CFR
Part 110. Additionally, a HACCP plan shall be documented, reviewed, and implemented.
In response to an EFSA request to provide information on the production yield (i.e. how much
cranberry juice is needed to produce a defined amount of the NF), the applicant informed that 66 mL
of pure (7.5 Brix) cranberry juice is needed to produce 145 mg of cranberry extract containing
33–36 mg PACs (about 80 mg measured by OSC-DMAC) and that this amount approximately
corresponded to a 240 mL serving of Ocean Spray’s 27% ‘cranberry juice classic’ currently on the
market.
The Panel considers that the production process is sufficiently described and does not raise
concerns about the safety of the novel food.
3.3. History of the organism used as a source of the NF
The source of the NF is cranberry (Vaccinium macrocarpon) juice. According to ANSES (2013),
cranberry juice has a history of food use in European Union (EU).
According to the applicant, cranberry juice products are sold globally and are marketed without
limitations on their consumption.
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The provided consumption data concern exclusively for the US. According to the US Agricultural
Marketing Resource Center, the annual consumption of cranberries per person is about 1 kg
cranberries, almost entirely in the form of juice or juice blends (AGMRC, 2016).
The estimated mean per-user daily intake of cranberries by male and female adults in the US is
23.6 and 42.1 g, respectively, and the estimated 90th percentile per-user daily intake of cranberries is
69.3 and 103.9 g/day, respectively (CDC, 2006). These intake estimates are based on food
consumption data included in the National Center for Health Statistics’ (NCHS), National Health and
Nutrition Examination Surveys (NHANES) (survey data from years 2003–2004, 2005–2006).
According to the NHANES of 2005–2008, the mean per-user daily intake consumption of cranberry
juice (100% cranberry juice, cranberry juice cocktail, low-calorie cranberry juice cocktail and blended
cranberry drinks) was 221 mL. Duffey and Sutherland (2013) considered that the amount of cranberry
juice in products to be around 27% due to the astringency of cranberry juice. The applicant concurs
with the assumption that ‘cranberry juice’ consumption as recorded by NHANES represents beverages
with about 27% cranberry juice and not the pure juice.
In response to a request by EFSA, the applicant provided data on the adults’ consumption of
cranberry beverage in the US NHANES (2013–2014), presented in Table 2 (per consumer only) and
Table 3 (per kg body weight (bw), consumer only). Following a request from EFSA regarding data on
cranberry juice consumption by children and regarding the target population, the applicant provided
intake estimates also for children, but confirmed that children are not the target group.
The applicant proposed to establish the safety of the NF on the basis of the history of consumption
of its source (cranberry juice), along with the provided compositional data on the source and on the
NF. Table 4 presents a comparison between the composition of pure (100%, 7.5 brix) and 27%
cranberry juice, cranberry juice cocktail and the contents of cranberry extract powder constituents at
the intended use level of the NF in beverages.
According to the applicant, 8 oz ( 240 mL) of 100% unsweetened cranberry juice contain 576 mg
PACs, 736 mg phenolics and 53 mg anthocyanins (Table 4). These values present the mean of 64
samples over several years. A mean PACs content of 156 mg/240 mL has been calculated by EFSA for
27% cranberry juice (27/100 of 576 mg PACs). To confirm this figure, the applicant referred to
analyses over the shelf-life of cranberry juice cocktail samples have resulted to a range of PACs
content from 70 to 140 mg/240 mL..
Table 2: Estimated daily intake of cranberry beverage in the US by adults
Population
group
Age group
(years)
Consumer-only Intake (mL/day)
%* n Mean
90th
percentile
95th
percentile
97.5th
percentile
Female Adults ≥ 20 2.1 60 203 310 1,201 1,201
Male Adults ≥ 20 1.5 30 166 314 379 521
Source: 2013–2014 NHANES Data.
*Percentage of consumers among survey population.
Table 3: Estimated daily per kilogram body weight intake of cranberry beverage in the US by adults
Population
group
Age group
(years)
Consumer-only Intake (mL/kg bw per day)
%* n Mean
90th
percentile
95th
percentile
97.5th
percentile
Female adults ≥ 20 2.1 60 2.2 5.0 7.4 7.4
Male adults ≥ 20 1.5 30 1.9 2.8 6.4 7.2
Bw: body weight. Source: 2013–2014. NHANES Data.
*Percentage of consumers among survey population.
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When assuming that 240 mL of 27% cranberry juice contains on average 156 mg PACs (0.65 mg/mL)
(Table 4, measured by the OSC-DMAC method), and that the mean and 95th percentile of an adult
female consumer is about 200 and 1,200 mL, respectively, cranberry juice per day (according to Table 2),
then the resulting estimated mean and 95th percentile PACs intake from cranberry juice products would
be about 130 and 780 mg PACs per day. The mean and 95th percentile daily PACs per kg bw for adult
females were 2.2 and 7.4 mL (Table 3) which would correspond to a PACs intake of 1.43 and 4.81 mg/kg
bw per day, respectively. For male adults, the mean and 95th percentile intakes of PACs from cranberry
juice would be 108 (1.24 mg/kg bw) and 246 mg (4.16 mg/kg bw) per day, respectively.
3.4. Anticipated intake/extent of use of the NF
3.4.1. Uses and use levels
Cranberry extract powder is intended to be added to fruit-flavoured drinks (regular and low
calorie), isotonic drinks (including electrolyte types), tea drinks (ready-to-drink, iced), vitamin-
enhanced waters, yogurts and yogurt drinks with the intention to provide 80 mg PACs per serving
(based on OSC-DMAC method). In order to achieve this level, the proposed food-uses and
corresponding use levels for cranberry extract powder are provided in Table 5.
The target population is the adult general population. Upon request from EFSA, the applicant
confirmed that the cranberry extract powder is not intended to be marketed to infants, toddlers and
children of below 19 years of age.
Table 4: Constituents of existing cranberry juice products and of beverages based on proposed use
levels of cranberry extract powder and naturally occurring constituents provided by the
applicant
Constituents
(mg/240 mL(a))
Cranberry beverage products
Proposed uses
in beverages100% cranberry juice
(unsweetened)
27%
cranberry
juice(c)
Cranberry juice
Cocktail
Cranberry extract
powder
0 0 0 144(d)
Proanthocyanidins 576(b) (481–916) 156 90 (70–140) 76.8(d)
Phenolics 736 199 211 61
Anthocyanins 53 14 12 12
Quinic acid 2,304 623 648 0.1
Malic acid 1,872 506 504 0.4
Citric acid 2,520 681 672 0.4
Quercetin – – 3 0.4
Galacturonic acid – – 288 –
Dextrose 7,512 2,030 16,372 0
Fructose 1,824 493 12,408 0
Sucrose 120 32 1,512 0
Ascorbic acid Not provided – 69.6 –
Water (mL) 222 – 207 –
(a): 240 mL  8 oz which is the amount considered as one portion size by the applicant.
(b): Mean and range on the basis of 64 samples over several years.
(c): These values are calculated on the basis of the provided figures for pure (100%) cranberry juice and does not consider any
addition other than water, noting that existing 27% cranberry juices on the market may contain higher amounts of some of
these constituents deriving from other fruit/vegetable juice used for blending.
(d): Calculated on the basis of a level equivalent to 150 mg cranberry extract powder and 80 mg PACs (by OSC-DMAC) per
250 mL beverage.
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Table 4 (last column) provides also information on the contents of cranberry extract powder
constituents (PACs, phenolics, anthocyanins and organic acids) at the intended use level of the NF in
beverages. The Panel notes that when the NF is added to 150 mL beverages or yogurts at the
intended use levels, the resulting contents of PACs per mL would be within the range reported for
cranberry juice cocktail or below the content in 27% cranberry juice.
3.4.2. Consumption data
For estimating intakes of the NF under the proposed uses and use levels for the target population
(i.e. adults), the applicant used the following UK surveys: United Kingdom Data Archive (UKDA) for the
NDNS: Adults Aged 16–64 years collected in 2000–2001 (NDNS 2000–2001) (Office for National
Statistics, 2005) and 1992–1993 (NDNS 1992–1993) (UKDA, 1995). Estimates for the intake of
cranberry extract powder by the UK population were generated and collated by computer, using
consumption data from individual dietary records, detailing food items ingested by each survey
participant on each of the survey days. Estimates for the daily intake of cranberry extract powder
represent projected 7-day averages for each individual of NDNS data. The distribution from which
mean and percentile intake estimates were produced was comprised of these average amounts.
The applicant also provided exposure calculations based on data from the EFSA Comprehensive
Food Consumption Database. Intake of cranberry extract powder was calculated for total population
and users only (either fermented milk products or soft drinks).
3.4.3. Intake estimate for cranberry extract powder
Table 6 summarises the estimated total intake of cranberry extract powder (mg/person per day)
from all proposed food-uses in the EU by population group. Table 7 presents this data on a per kilogram
body weight basis (mg/kg bw per day). When all-user consumers (mean and 95th percentile) were
assessed, the estimates for the intakes of cranberry extract powder from adult food-uses were
determined to be at 123 and 366 mg/day for male adults and at 114 and 319 mg/day for female adults,
respectively. On a body weight basis, the all-user mean and 95th percentile intake estimates of
cranberry extract powder for adults were at 1.5–1.7 and 4.3–4.7 mg/kg bw per day, respectively
(Table 7).
Table 5: Summary of proposed individual food uses and use of cranberry extract powder in the
European Union (NDNS data)
Food
category
Proposed food-uses
Cranberry extract
powder
(mg/portion)(a)
Portion
(g or mL)(b)
Level of use of
cranberry extract
powder (%)
Beverages Fruit-flavoured beverages (regular)(c) 150 250 0.06
Isotonic beverages (including those
containing electrolytes)
150 250 0.06
Low-calorie fruit-flavoured beverages 150 250 0.06
Tea beverages (ready-to-drink, iced)(d) 150 250 0.06
Vitamin waters 150 330 0.045
Milk and dairy
products
Yogurts 150 125 0.12
Yogurt drinks 150 200 0.075
(a): The quantity of cranberry extract powder was calculated on the basis of a level equivalent to 80 mg (by OSC-DMAC)
proanthocyanidins/portion (approx. 55–60% of PACs are present in cranberry extract powder).
(b): The portions are based on the UK’s ‘Food Portions Sizes’ handbook. Food Standards Agency (3rd edition; FSA, 2002).
(c): Not low-calorie beverages.
(d): As the NDNS databases (1992–1993, 1997, 2000–2001) do not include food codes for tea drinks (ready-to-drink, iced)
specifically, food codes for herbal teas (ready-to-drink) were used as surrogates.
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Using the EFSA Comprehensive Food Consumption Database, estimated total intake levels of
cranberry powder extract were highest in adults, with a range of 167–885 mg/day at the 95th
percentile. Among users of fermented milk products only, the estimated intake levels were also highest
with adults, with a range of 135–717 mg/day at the 95th percentile. Among users of soft drinks only,
estimated intakes were highest in adults, with a range of 198–819 mg/day at the 95th percentile. The
applicant maintained that the intake levels using the EFSA Database are likely to overestimate as
compared to the intake levels derived using the UK NDNS database. This is because the exposure
assessment conducted in the UK NDNS survey was specified at a food-code level, thereby allowing a
more specific matching of the fortified food-use concentration data, whereas the EFSA Database uses
a food category level.
3.4.4. Intake estimate for PACs of cranberry extract powder
Cranberry extract powder contains a maximum of 60% PACs (Table 1). The total estimated daily
all-person and all-user adult intakes of PACs from all proposed uses of cranberry extract powder are
presented in Table 8 and Table 9 on an mg/day and mg/kg bw per day basis, respectively. It should be
noted that only the all-user intake results will be discussed in detail.
For female adults, the mean and 95th percentile estimates for the all-user intakes of PACs from all
proposed food-uses were 68 mg/day (1.0 mg/kg bw per day) and 192 mg/day (2.8 mg/kg bw per
day), respectively. The mean and 95th percentile estimates for the all-user intakes for male adults of
PACs from all proposed food-uses also were 74 mg/day (0.9 mg/kg bw per day) and 219 mg/day
(2.6 mg/kg bw per day), respectively.
Table 6: Estimated daily intake of cranberry extract powder from all proposed food categories in
the EU by adults (1992–1993, 2000–2001 NDNS Data)
Population
group
Age
group (years)
% user
All-person consumption All-users consumption
Mean
(mg)
Percentile (mg) Mean
(mg)
Percentile (mg)
90th 95th 90th 95th
Female adults 16–64 60.8 76 206 278 114 243 319
Male adults 16–64 54.3 72 208 298 123 281 366
Table 7: Estimated daily per kilogram body weight intake of cranberry extract powder from all
proposed food categories in the EU by adults (1992–1993, 2000–2001 NDNS Data)
Population
group
Age group
(years)
% user
All-person consumption All-users consumption
Mean
(mg/kg)
Percentile
(mg/kg) Mean
(mg/kg)
Percentile
(mg/kg)
90th 95th 90th 95th
Female adults 16–64 60.8 1.0 2.9 3.8 1.7 3.6 4.7
Male adults 16–64 54.3 0.8 2.4 3.6 1.5 3.4 4.3
Table 8: Estimated daily intake of PACs resulting from all proposed food-uses of cranberry extract
powder in the adult EU population (1992–1993, 2000–2001 NDNS Data)
Population
group
Age group
(years)
% user
All-person consumption All-user consumption
Mean
(mg)
Percentile (mg)
Mean (mg)
Percentile (mg)
90th 95th 90th 95th
PACs (OSC-DMAC)
Female adult 16–64 60.8 46 123 167 68 146 192
Male adult 16–64 54.3 43 125 179 74 168 219
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3.5. Information from previous exposure to the NF or its source
According to the applicant, cranberry juice and cranberry cocktails are widely consumed throughout
Europe. Marketing data indicates that, from 2010, the European consumption of the applicant’s
cranberry juice cocktail equated to 200 million litres. Recent market data from the European Juice
Industry (AIJN, 2012 – Liquid Fruit Market Report) further estimated the import of cranberry
concentrate to be equivalent to consumption of cranberry juice cocktail of 300 million litres. In
addition, many different cranberry food supplement products are available in Europe.
The applicant estimated the intake of PACs from consumption of Ocean Spray’s cranberry extracts
to be 17.1% (analysed using BL-DMAC method) using adult data set from the Netherlands which was
found to be the Member State with the highest intake of Ocean Spray’s cranberry extract. The mean
and 95th percentile intakes for PACs were 74.4 and 162.2 mg/day (when using the OSC-DMAC method
the reported PACs content was about 60% which would result in approximately three times higher
PACs intakes).
3.6. Nutritional information on the NF
In response to Member State concerns, the applicant provided literature data on polyphenols from
different food matrices and folic acid transport (Martel et al., 2010; Couto et al., 2012), iron absorption
(Bentivegna and Whitney, 2002; Yamakoshi et al., 2002; Erdman et al., 2007; Fujii et al., 2008; Hurrell
and Egli, 2010; Ma et al., 2011), absorption of lipids including triglycerides (Erdman et al., 2007;
Sugiyama et al., 2007; Toyoda-Ono et al., 2007; Blade et al., 2010; Chen et al., 2011; Jakobek, 2015),
possible interaction with carrier proteins (Faria et al., 2006; Yang and Pan, 2012; Jakobek, 2015), and
potential interaction with warfarin (Greenblatt et al., 2006; Grenier et al., 2006 Lilja et al., 2007; Zikria
et al., 2010). The Panel notes that nutritional information is available for foods other than cranberry
PACs. The Panel considers that, based on the available literature on polyphenols, there is no reason to
assume that consumption of cranberry PACs would lead to dissimilar nutritional consequences in
comparison to consumption of other polyphenol containing foods.
Taking into account the composition of the novel food and the intended use levels, the
Panel considers that the consumption of the NF is not nutritionally disadvantageous.
3.7. Microbiological information on the NF
The Panel considers that the microbiological information provided (Table 1) does not raise safety
concerns.
3.8. Toxicological information on the NF
In absence of toxicological studies on the NF, the applicant provided toxicological information on
other source of PACs, namely grape seed extract (GSE) and on phenolic acids (e.g. chlorogenic acid)
as supporting evidence for the safety of the NF. The Panel notes, however, that the types of PACs in
the NF are not the same as in GSE (with differences in the composition of monomeric, dimeric,
trimeric, oligomeric and polymeric PACs and the A-type linkages typical to cranberries). The
Panel considers that these studies are not pertinent for assessing the safety of the NF.
Table 9: Estimated daily per kilogram body weight intake of PACs resulting from all proposed food-
uses of cranberry extract powder in the adult EU population (1992–1993, 2000–2001
NDNS Data)
Population
group
Age group
(years)
% user
All-person consumption All-user consumption
Mean
(mg/kg bw)
Percentile
(mg/kg bw) Mean
(mg/kg bw)
Percentile
(mg/kg bw)
90th 95th 90th 95th
PACs (OSC-DMAC)
Female adult 16–64 60.8 0.6 1.8 2.3 1.0 2.2 2.8
Male adult 16–64 54.3 0.5 1.4 2.2 0.9 2.1 2.6
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3.8.1. Absorption, distribution, metabolism and excretion
The toxicokinetic properties of PACs have not been extensively evaluated. However, it has been
demonstrated that only the PACs with a low degree of polymerisation (i.e. dimers) can be absorbed,
and that the extent of their absorption is low (Cos et al., 2003; Prior and Gu, 2005). In vitro studies
suggest that PAC polymers could be degraded into monomers under the acidic conditions of the
stomach, although this is not thought to occur readily in humans (Manach et al., 2005). Rather, it has
been proposed that oligomeric and polymeric PACs are transported to the large intestine where they
undergo degradation by the colonic microbiota into simple phenolic acids which can then be
subsequently absorbed (Manach et al., 2005; Prior and Gu, 2005).
3.8.2. Genotoxicity
Lack of genotoxicity with three different commercial cranberry products with low doses of phenolics
was reported in the Palikova et al. (2010) rat study. However, the Panel considers that this study is not
pertinent for assessing the genotoxicity of the NF. The Panel considers that the genotoxicity risk
related to the consumption of the NF is not higher than the risk related to the consumption of
cranberry juice.
3.8.3. Subacute and subchronic toxicity studies
No data was provided on the NF.
3.8.4. Subchronic toxicity studies
In its 2011 comments, ANSES asked the applicant to conduct a 90-day study in accordance with
OECD guidelines as well as a mutagenicity study on the product in this application. In its response of
17 September 2012, the applicant noted that ‘these studies were not considered to be necessary since
safety has been demonstrated through history of consumption and pre-clinical and clinical data using
cranberry products with a similar PAC content’.
Instead, the applicant referred to one controlled 14-week study with male Wistar rats fed with
three different commercial cranberry products (Palikova et al., 2010). The Panel notes that this study
was not performed according to the respective OECD Guidance. The Panel also notes the low dose
tested (i.e. up to 0.60 mg PACs/kg bw per day). The Panel considers that this study is of no relevance
for the safety of the NF at the proposed uses and use levels.
3.8.5. Human studies
While no animal toxicological studies have been conducted on the Ocean Spray product, a number
of human clinical studies have been conducted with cranberry juice cocktails containing 30%
concentrates (30–300 mL/day), or cranberry capsules (400–7,500 mg/day) (Jepson et al., 2008). None
of these studies have indicated adverse effects caused by cranberry consumption. Although the
phenolic composition of the test articles were not specified in these studies, the applicant assumes
from the BL-DMAC analysis of several different cranberry extract products provided above that the
PACs values used in the studies would be similar to that of the Ocean Spray product with added
cranberry extract (meaning the NF).
ANSES published an opinion on the potential effects of cranberry on community-acquired urinary
tract infection, which included an evaluation of the safety of cranberry juices and supplements based on
data from these published clinical trials (ANSES, 2011). The opinion noted that side effects associated
with the consumption of cranberry products were predominantly gastrointestinal in nature (such as
gastroesophageal reflux, nausea and digestive disorders), and were observed particularly when large
amounts of cranberry beverage were consumed for prolonged periods. No adverse findings or
alterations in haematological and clinical biochemistry parameters were observed in one study where 65
healthy females consumed 400 mg/day (PACs content not reported) of a cranberry juice extract for
8 weeks (Valentova et al., 2007). ANSES concluded that ‘in the current state of knowledge, there is no
safety concern related to the consumption of cranberry by the general population’ (ANSES, 2011).
In addition to the clinical study evaluated within the ANSES opinion (2011), three clinical studies
have been conducted with Ocean Spray’s cranberry extract powder. In these randomized, double-blind,
placebo-controlled trials 54–140 adults received cranberry extract providing 36 mg or 72 mg PACs
(measured by using the BL-DMAC method; when using the OSC-DMAC method the reported PACs
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content would result to approximately three times higher values) daily for 10–12 weeks (Nantz et al.,
2009; Juturu et al. 2015, manuscript; one unpublished report). Neither difference in the numbers of
adverse effects was noted nor adverse effects on blood biochemistry or haematology. The Panel notes
that the PACs dose of these studies is high as compared to the conditions of use of the NF. The
Panel considers these studies do not raise safety concerns of the NF.
3.9. Allergenicity
No cases of an allergic reaction to cranberries or cranberry extract have been identified in the
scientific literature. As stated earlier, the level of residual protein in the NF is 1.16%.
The Panel considers that the allergenic risk of the novel food is not dissimilar as of other cranberry
products.
4. Discussion
The applicant provided sufficient information regarding the composition, production, stability and
the estimated intake of the cranberry extract powder.
The NF is prepared from the juice concentrate of the cranberry cultivar (Vaccinium macrocarpon),
and contains 55–60% PACs as measured by OSC-DMAC. During the manufacturing process, these
phenolic compounds are selectively isolated from the other components of cranberry juice (e.g. sugars
and organic acids) to yield cranberry extract. The amount of the cranberry juice needed to produce a
defined amount of the NF corresponds to a 240 mL serving of Ocean Spray’s 27% ‘cranberry juice
classic’ currently on the market. The source has a history of human consumption.
The NF is intended to be added to fruit-flavoured drinks (regular and low calorie), isotonic drinks
(including electrolyte types), tea drinks (ready-to-drink, iced), vitamin enhanced waters, yogurts and
yogurt drinks with the intention to provide 80 mg PACs per serving (based on OSC-DMAC method).
According to the applicant, the target population is the adult general population and the NF is not
intended to be marketed to children.
The mean and 95th percentile volume consumption of a 27% cranberry juice drink for an adult female
is about 200 and 1,200 mL, respectively. Assuming that 240 mL of 27% cranberry juice contains on
average 156 mg PACs, the corresponding mean and 95th percentile intakes of PACs from cranberry juice
would be about 130 and 780 mg PACs per day for adult females and 108 and 246 mg for adult males.
For female adults, the mean and 95th percentile estimates for the all-user intakes of PACs from all
proposed food-uses of the NF were 68 mg/day and 192 mg/day, respectively. The mean and 95th
percentile estimates for the all-user intakes for male adults of PACs from all proposed food-uses also
were 74 mg/day and 219 mg/day, respectively.
Taking into account the composition of the novel food and the intended use levels, the
Panel considers that the consumption of the NF is not nutritionally disadvantageous.
While no animal toxicological studies have been conducted on the NF, a number of human clinical
studies have been conducted with cranberry products other than the NF. None of these studies have
indicated adverse effects caused by cranberry consumption. In addition, three clinical studies have
been conducted with the NF. The Panel notes that the PACs dose of these clinical studies is high as
compared to the conditions of use of the NF. The Panel considers these studies do not raise safety
concerns of the NF.
Based on the data provided, and considering the composition, manufacturing process, anticipated
intake, history of consumption of the source, and human studies, the Panel considers that the
consumption of the cranberry extract powder under the proposed conditions of use does not raise
safety concerns.
5. Conclusions
The Panel concludes that the cranberry extract powder is safe as a food ingredient at the proposed
uses and use levels.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the request
for a scientific opinion on the safety of cranberry extract powder a novel food ingredient. Ref.
Ares(2016)1870715, dated 20 April 2016.
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2) On 28 April 2016, EFSA received the following documentation: dossier ‘cranberry extract
powder’, which was submitted by Ocean Spray Cranberries Inc.; initial assessment report
carried out by the French Agency for Food, Environmental and Occupational Health regarding
the evaluation of an application for authorisation to market a novel ingredient: ‘cranberry
extract powder’ under Regulation (EC) No 258/97 concerning novel foods; Member States’
comments and objections; response by the applicant to the initial assessment report.
3) On 14 June 2016, EFSA sent a request to the applicant to provide missing information to
accompany the application.
4) On 20 July 2016, EFSA received the missing information as submitted by the applicant. After
checking the content of the full dossier, including the missing information, EFSA considered
the application valid as of 24 August 2016.
5) On 25 October and 7 December 2016, and 11 January 2017, EFSA sent requests to the
applicant to provide additional information to accompany the application.
6) Additional data were provided by the applicant on 14 November and 19 December 2016, and
13 January 2017.
7) During its meeting on 4–6 April 2017, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of ‘cranberry extract powder’ as a novel food pursuant to
Regulation (EC) No 258/97.
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AOAC Association of Official Analytical Chemists
APHA American Public Health Association
BAM Bacteriological Analytical Manual
BL-DMAC Brunswick Laboratories - 4-dimethylaminocinnamaldehyde
bw bodyweight
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cfu colony forming units
DWB dry weight basis
FDA (US) Food and Drug Administration
GAE gallic acid equivalent
GMP good manufacturing practice
GSE grape seed extract
HAACP hazard analysis and critical control point
MOE margin of exposure
mpn most probably number
NF novel food
NFI novel food ingredient
OECD Organisation for Economic Co-operation and Development
OSC-DMAC Ocean Spray Cranberries-4-dimethylaminocinnamaldehyde
NCHS National Center for Health Statistics
NDNS National Diet and Nutrition Survey
NHANES National Health and Nutrition Examination Surveys
PACs proanthocyanidins
UKDA United Kingdom Data Archive
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